MediWound Ltd. $MDWD is Yelin Lapidot Holdings Management Ltd.’s 9th Largest Position

Yelin Lapidot Holdings Management Ltd. decreased its holdings in shares of MediWound Ltd. (NASDAQ:MDWD) by 4.8% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 816,741 shares of the biopharmaceutical company’s stock after selling 41,259 shares during the period. MediWound makes up approximately 2.9% of Yelin Lapidot Holdings Management Ltd.’s investment portfolio, making the stock its 9th largest holding. Yelin Lapidot Holdings Management Ltd. owned 7.56% of MediWound worth $15,820,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. Corebridge Financial Inc. increased its holdings in shares of MediWound by 17.1% in the first quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 665 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after acquiring an additional 999 shares in the last quarter. Deutsche Bank AG grew its holdings in MediWound by 2,255.2% in the first quarter. Deutsche Bank AG now owns 6,312 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 6,044 shares during the period. Nuveen LLC acquired a new stake in MediWound in the 1st quarter valued at $168,000. Finally, Rhumbline Advisers increased its stake in shares of MediWound by 4.4% during the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 481 shares in the last quarter. 46.83% of the stock is owned by institutional investors and hedge funds.

MediWound Stock Performance

NASDAQ:MDWD opened at $18.03 on Friday. The stock has a 50-day simple moving average of $17.83 and a 200-day simple moving average of $18.82. The stock has a market cap of $199.90 million, a P/E ratio of -6.83 and a beta of 0.22. MediWound Ltd. has a 1 year low of $14.14 and a 1 year high of $22.50.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.68). MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%.The company had revenue of $5.71 million for the quarter, compared to analysts’ expectations of $5.68 million. On average, equities research analysts predict that MediWound Ltd. will post -2.66 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on MDWD. Wall Street Zen cut MediWound from a “hold” rating to a “sell” rating in a research report on Friday, July 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a report on Wednesday, October 8th. Finally, Zacks Research lowered shares of MediWound from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th. Four investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $32.25.

MediWound Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.